


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.62%
-0.92%
+1.09%
-11.46%
OCGN
Ocugen
$1.45
Strengths

Upgraded on attractively valued
Risk Analysis

Earnings are forecast to decrease
OCGN Price Performance
$1.45 (0.00%)
$1.41 (+2.84%)
$1.03 (+40.78%)
$0.73 (+98.63%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
![]()
OCGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
OCGN Street Sentiment is unimpressive and have negative views on the near-term outlook
OCGN has Extreme risk level
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Average key support and resistance price levels
MGTX
MeiraGTx Holdings pl
7.61
-1.68%
LCTX
Lineage Cell Therape
1.46
-7.01%
CGTX
Cognition Therapeutics
1.09
-12.10%
ADEA
Adeia
18.09
-0.11%
OCGN
Ocugen
1.45
-4.61%
PROF
Profound Medical Cor
7.50
+0.27%
BTCS
BTCS
2.24
-11.46%
ANVS
Annovis Bio
2.70
-5.45%
What is OCGN current stock price?
What are OCGN stock strengths?
What is OCGN Risk Level?
What is OCGN market cap and volume?
What is OCGN current Stock IQ?
Should I buy OCGN stock right now?
Is OCGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for OCGN?
What does a 'Strong Sell' rating mean for OCGN?
What factors influence OCGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.62%
-0.92%
+1.09%
-11.46%
OCGN
Ocugen
Current Price
$1.45
Linked to OCGN
MGTX
MeiraGTx Holdings pl
7.61
-1.68%
LCTX
Lineage Cell Therape
1.46
-7.01%
CGTX
Cognition Therapeutics
1.09
-12.10%
Recently Viewed
ADEA
Adeia
18.09
-0.11%
OCGN
Ocugen
1.45
-4.61%
PROF
Profound Medical Cor
7.50
+0.27%
BTCS
BTCS
2.24
-11.46%
ANVS
Annovis Bio
2.70
-5.45%

OCGN Price Performance
$1.45 (0.00%)
$1.41 (+2.84%)
$1.03 (+40.78%)
$0.73 (+98.63%)
OCGN Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
![]()
OCGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
OCGN Street Sentiment is unimpressive and have negative views on the near-term outlook
OCGN has Extreme risk level
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Average key support and resistance price levels
OCGN Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued
Risk Analysis

Earnings are forecast to decrease
OCGN Latest Analysis
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering. ) shares sank sharply on Wednesday after the biotech company announced a $22.5 million underwritten offering of common stock. Here’.s what investors .The company is issuing 15 million new shares at $1.50 apiece with all shares ...
Wed Jan 21, 2026
Ocugen prices $22.5M common stock offering at $1.50 per share.
Wed Jan 21, 2026
Ocugen Inc. Announces Pricing of $22.5 Million Offering of Common Stock. MALVERN Pa. Jan. 21 2026 (GLOBE NEWSWIRE) -- Ocugen Inc. (NASDAQ:) a pioneering biotechnology leader in gene therapies for blindness diseases today announced the pricing of its underwritten offering of 15000000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million before deducting commissions and other estimated offering expenses payable by Ocugen. The offerin
Wed Jan 21, 2026
Ocugen: Why I Dont Read Too Much Into The Selloff On Phase 2 GA Data.
Fri Jan 16, 2026
Ocugens Early Gene Therapy Data Shows 46% Drop In Vision Damage. ) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410 a gene therapy .The stock’.s decline comes as the broader market is experiencing gains with major indices such as the S&.P 500 up 0.64% and the Nasdaq gaining 1.07%.Preliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion growth compared to the control group after 12 months with no serious adverse events rep
Thu Jan 15, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
OCGN Stock trends
OCGN Stock performance
OCGN Stock analysis
OCGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.